A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

NCT07064122 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Haematologic Neoplasms

Interventions

DRUG: AZD2962

Sponsor

AstraZeneca

Collaborators

[object Object]